- Admin
- #1
BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the COVID-19 vaccine it developed with Pfizer , but the German biotech firm is still forecasting a full-year decline in vaccine sales. "As a result of an increased order volume initially placed in late 2021 following the then-emerging Omicron variant, we began the year 2022 with strong revenues and earnings, leaving us well-positioned to achieve the 2022 financial guidance," finance chief Jens Holstein said. BioNTech stood by its 2022 vaccine revenue guidance of 13 to 17 billion euros, down from 19 billion last year, implying a decline during the rest of the year.